Core Insights - TuHURA Biosciences has demonstrated for the first time that the Delta Opioid Receptor (DOR) is expressed on tumor-associated myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs), indicating a new target for overcoming resistance to cancer immunotherapy [1][2][4] - The research highlights the potential of DOR antagonism to reprogram the immunosuppressive capabilities of MDSCs and TAMs, which are critical components of the tumor microenvironment [2][4] - TuHURA is set to present these findings at the 67th American Society of Hematology (ASH) Annual Meeting in December 2025, showcasing the implications of DOR inhibition in enhancing cancer treatment efficacy [1][3][4] Company Developments - TuHURA is developing novel technologies aimed at overcoming both primary and acquired resistance to cancer immunotherapy, which are common reasons for treatment failure [6][8] - The company is advancing its lead innate immune agonist, IFx-2.0, in a Phase 3 trial as an adjunctive therapy to Keytruda (pembrolizumab) for advanced or metastatic Merkel Cell Carcinoma [7][8] - TuHURA has also acquired TBS-2025, a VISTA inhibiting monoclonal antibody, which is moving into Phase 2 development for patients with mutant NPM1 relapsed/refractory acute myeloid leukemia (AML) [8] Research Presentations - An oral presentation titled "Delta Opioid Receptor (DOR) Expression on Myeloid-Derived Suppressor Cells (MDSCs) Represents a Novel Target to Overcome Resistance to Immune Checkpoint Inhibitors (ICIs)" will be presented by Mike Turner, Ph.D., on December 7, 2025 [3] - A poster presentation on "Delta Opioid Receptor (DOR): A Novel Target for Reprogramming Tumor-Associated Macrophage (TAM) Immunosuppressive Phenotype" will be presented by Krit Ritthipichai, D.V.M., Ph.D., on December 6, 2025 [4] - The Moffitt Cancer Center will also present findings on the pathogenic role of DOR-expressing MDSCs in patients with myeloid dysplastic syndrome (MDS) [4]